Cerebral ischemia induces BBB disruption and the thrombolytic t-PA has been shown to aggravate this process (Latour et al., 2004) which accelerates with time from symptom onset, representing the underlying cause of an increased bleeding risk associated with late t-PA treatment, the main obstacle to a more widespread use of this stroke therapy. The gene discussed is PLAT; the disease is stroke disorder.